[Form 4] Senti Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 overview: On 06/25/2025, Senti Biosciences (ticker SNTI) reported granting director Feng Hsiung a stock option for 21,950 common shares at an exercise price of $2.05 per share.

The option, filed on 06/27/2025, vests 100 % on the earlier of (i) the first anniversary of the grant or (ii) the 2026 annual shareholders’ meeting, subject to continued board service. It carries a 10-year term with an expiration date of 06/24/2035.

No open-market purchase or sale of common shares occurred; the transaction is strictly an equity-based compensation award. After the grant, Mr. Hsiung beneficially owns 21,950 derivative securities, and the filing shows no change to his direct or indirect ownership of outstanding common shares. The disclosure does not reference a Rule 10b5-1 trading plan.

Investor take-away: This is a routine director compensation event that modestly aligns board incentives with shareholder value. It creates potential dilution only if exercised and has no immediate impact on cash flow, operations, or the company’s financial outlook. The Form 4 contains no earnings or operational data.

Insights

Securities Analyst

TL;DR: Routine director option grant; negligible financial or market impact for SNTI shareholders.

The 21,950-share option award at $2.05 is standard board compensation, representing well under 1 % of SNTI’s outstanding shares. Because it vests over a year and has a 10-year life, any dilution is distant and contingent on share-price appreciation. No insider buying or selling of common stock is disclosed, and there is no Rule 10b5-1 plan involved. From a cash-flow and P&L standpoint, the only effect is non-cash stock-based compensation expense, which is immaterial at this size for a public company. Consequently, the filing is considered informational rather than market-moving.

Corporate Governance Expert

TL;DR: Grant aligns director incentives but is ordinary-course governance; no red flags detected.

Boards typically refresh equity awards annually to maintain alignment with shareholder interests. The single-tranche vesting tied either to a one-year cliff or the 2026 AGM is typical for small-cap biotech firms and promotes continuity of service. The option price mirrors recent trading ranges, avoiding discounted grants. Signature by attorney-in-fact and prompt filing (within two business days) meet compliance standards. No issues of late reporting or preferential terms emerge, so governance risk remains low.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hsiung Feng

(Last) (First) (Middle)

C/O SENTI BIOSCIENCES, INC.

2 CORPORATE DRIVE FIRST FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Senti Biosciences, Inc. [ SNTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.05	06/25/2025		A		21,950		(1)	06/24/2035	Common Stock	21,950	$0	21,950	D

Explanation of Responses:

1. 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Robert Cutler, attorney-in-fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did SNTI report in its latest Form 4?

Senti Biosciences granted director Feng Hsiung a stock option for 21,950 shares at an exercise price of $2.05.

How many options were granted to the SNTI director and at what price?

A total of 21,950 options were granted with an exercise price of $2.05 per share.

When will the granted options to Feng Hsiung vest?

They vest 100 % on the earlier of 06/25/2026 or the date of the 2026 Annual Meeting, subject to continued service.

What is the expiration date of these SNTI stock options?

The options expire on 06/24/2035, providing a 10-year exercise window once vested.

Does this Form 4 filing affect SNTI’s share count or earnings immediately?

No. It is a routine equity award with no immediate cash impact and only potential future dilution if exercised.